Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | UGCG | Q16739 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8113253 | 1.00 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL9327248 | 0.89 | MAPT (0.46) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL14288987 | 0.89 | MAPT (0.44) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL9567734 | 0.89 | MAPT (0.46) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL11431737 | 0.89 | MAPT (0.46) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL9814590 | 0.89 | MEN1 (0.38) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL28435235 | 0.88 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL28473803 | 0.88 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL3731770 | 0.88 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 | |
| SCHEMBL27461765 | 0.88 | MAPT (0.43) | MAPTPDE3ASLC22A6SLC22A8SLC22A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0076621-B1 | AZETIDINONE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 1987-09-23 | — | — | EP | claimed |
| EP-0043205-B1 | PENICILLIN DERIVATIVES | BEECHAM GROUP PLC (GB) | 1984-09-26 | — | — | EP | claimed |
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1054891-A1 | PRODRUGS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999041275-A1 | PRODRUGS | MEDIVIR AB (SE) | 1999-08-19 | — | — | WO | disclosed |
| EP-0350210-A2 | Novel 6-amido-1-methyl-2-(substituted-thio)-carbapenems | MERCK & CO. INC. (US) | 1990-01-10 | — | — | EP | disclosed |
| EP-0350211-A2 | Novel 6-amido-1-methyl carbapenems | MERCK & CO. INC. (US) | 1990-01-10 | — | — | EP | disclosed |
| US-4826833-A | ANTIBIOTICS | PFIZER INC. (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0222022-A1 | PROCESS FOR PRODUCING BETA-LACTAM DERIVATIVES | Otsuka Kagaku Kabushiki Kaisha (JP) | 1987-05-20 | — | — | EP | disclosed |
| EP-0150984-A2 | 6-(Substituted) methylenepenicillanic and 6-(substituted) hydroxymethylpenicillanic acids and derivatives thereof | PFIZER INC. (US) | 1985-08-07 | — | — | EP | disclosed |
| EP-0043205-B1 | PENICILLIN DERIVATIVES | BEECHAM GROUP PLC (GB) | 1984-09-26 | — | — | EP | disclosed |
| US-4416883-A | ANTIBIOTICS | BEECHAM GROUP LIMITED (GB) | 1983-11-22 | — | — | US | disclosed |
| EP-0043205-A1 | Penicillin derivatives | BEECHAM GROUP PLC (GB) | 1982-01-06 | — | — | EP | disclosed |
| US-4144391-A | REPLACING AN ACETOXY GROUP BY A SULFUR NUCLEOPHILE | ELI LILLY AND COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | MAPT 4482/4885PDE3A 1375/4885SLC22A6 834/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | MAPT 3289/4885PDE3A 2205/4885SLC22A6 554/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | MAPT 4482/4885PDE3A 1375/4885SLC22A6 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.